This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Quality of Life  • Endocrine Diseases  • Diabetes Mellitus  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Great Benefits, Special Risks

Arch Intern Med. 1999;159:541-542.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE BEST APPROACH for the treatment of hypertension in diabetic patients is a subject of much debate. However, data from a variety of studies, including the Hypertension Optimal Treatment (HOT) study,¹ Syst-Eur trial,² and the Symbolic Hypertension in the Elderly Program (SHEP),³ show that the treatment of hypertension in diabetic patients lowers cardiovascular mortality and events to a greater extent than in the nondiabetic population. Moreover, results from the UK Prospective Diabetes Study (UKPDS) trial⁴ showed a 37% reduction in microvascular end points, with differences in systolic and diastolic blood pressure of only 10 mm Hg and 5 mm Hg, respectively, between the more tightly controlled and less tightly controlled groups. Therefore, much benefit is possible from aggressive treatment of hypertension in the diabetic population.

In the study by Lakshman and colleagues⁵ in this issue of the ARCHIVES, it is concluded that, since none of the 6 antihypertensive agents studied . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Antihypertensives: Much Ado About Lipids
Beatrice A. Golomb and Michael H. Criqui
Arch Intern Med. 1999;159(6):535-537.
EXTRACT | FULL TEXT  

Diuretics and -Blockers Do Not Have Adverse Effects at 1 Year on Plasma Lipid and Lipoprotein Profiles in Men With Hypertension
M. Raj Lakshman, Domenic J. Reda, Barry J. Materson, William C. Cushman, Edward D. Freis, and for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents
Arch Intern Med. 1999;159(6):551-558.
ABSTRACT | FULL TEXT